Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PROF 
Profound Medical Corp (PROF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PROF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $12.1
1 Year Target Price $12.1
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.51% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 180.32M USD | Price to earnings Ratio - | 1Y Target Price 12.1 |
Price to earnings Ratio - | 1Y Target Price 12.1 | ||
Volume (30-day avg) 5 | Beta 0.25 | 52 Weeks Range 3.90 - 11.42 | Updated Date 06/30/2025 |
52 Weeks Range 3.90 - 11.42 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -269.39% | Operating Margin (TTM) -426.02% |
Management Effectiveness
Return on Assets (TTM) -38.54% | Return on Equity (TTM) -66.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 135085325 | Price to Sales(TTM) 15.2 |
Enterprise Value 135085325 | Price to Sales(TTM) 15.2 | ||
Enterprise Value to Revenue 11.39 | Enterprise Value to EBITDA -5.75 | Shares Outstanding 30053100 | Shares Floating 27606516 |
Shares Outstanding 30053100 | Shares Floating 27606516 | ||
Percent Insiders 17.35 | Percent Institutions 47.21 |
Analyst Ratings
Rating 3 | Target Price 12.1 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Profound Medical Corp
Company Overview
History and Background
Profound Medical Corp. is a medical technology company focused on developing and commercializing customizable, incision-free therapies for localized disease. Founded in 2008, it has evolved into a commercial-stage company with its TULSA-PRO technology.
Core Business Areas
- TULSA-PRO: Profound Medical's primary focus is on the TULSA-PRO system, a minimally invasive technology for ablating prostate tissue in men with localized prostate cancer.
Leadership and Structure
The leadership team includes Arun Menawat (CEO) and key executives in finance, operations, and clinical development. The organizational structure is typical of a publicly traded medical device company.
Top Products and Market Share
Key Offerings
- TULSA-PRO: TULSA-PRO is a transurethral ultrasound ablation system designed to provide predictable, customizable, and incision-free prostate tissue ablation. Market share data is evolving, but the company is targeting a segment of the prostate cancer treatment market. Competitors include traditional surgery (TURP, prostatectomy), radiation therapy, and other ablation technologies like cryotherapy and HIFU. No specific revenue from this product has been publicly disclosed in detail. Main competitors: EDAP TMS (HIFU).
Market Dynamics
Industry Overview
The industry is characterized by growing demand for minimally invasive cancer treatments, driven by an aging population and a desire for improved quality of life post-treatment.
Positioning
Profound Medical positions itself as offering a unique combination of precision, customization, and minimal invasiveness in prostate cancer treatment, potentially offering a competitive advantage over traditional methods.
Total Addressable Market (TAM)
The TAM for prostate cancer treatments is estimated to be in the billions of dollars. Profound Medical is positioned to capture a segment of this market with its TULSA-PRO technology.
Upturn SWOT Analysis
Strengths
- Minimally invasive technology
- Customizable treatment planning
- Potential for reduced side effects compared to traditional treatments
Weaknesses
- Limited clinical data compared to established treatments
- Relatively new technology requiring physician training and adoption
- Limited market penetration and brand awareness
Opportunities
- Expanding clinical indications for TULSA-PRO
- Increasing awareness and adoption by urologists
- Strategic partnerships with hospitals and clinics
- Market growth due to the growing incidence of prostate cancer.
Threats
- Competition from established prostate cancer treatments
- Regulatory hurdles and reimbursement challenges
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- EDAP TMS (EDAP)
- Intuitive Surgical (ISRG)
- Accuray Incorporated (ARAY)
Competitive Landscape
Profound Medical's advantage lies in its TULSA-PRO technology's unique features, but it faces challenges due to its limited market presence and competition from established companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth requires access to recent company filings.
Future Projections: Future Projections requires access to recent company filings and analyst estimates.
Recent Initiatives: Recent initiatives include expanding clinical trials, securing regulatory approvals, and commercializing TULSA-PRO in new markets.
Summary
Profound Medical is a company with a novel technology in the prostate cancer treatment space. TULSA-PRO offers a minimally invasive alternative with customizable treatment planning which is promising but the company faces competition from established treatments and companies and must continue to demonstrate its clinical value and expand its market reach. Financial performance needs to be assessed and further information needs to be provided in terms of revenue, profit and cash flows. The key is demonstrating clinical superiority and market adoption.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (where available)
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. Investment decisions should be made after conducting thorough research and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Profound Medical Corp
Exchange NASDAQ | Headquaters Mississauga, ON, Canada | ||
IPO Launch date 2016-06-09 | Chairman of the Board & CEO Dr. Arun Swarup Menawat MBA, Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 142 | Website https://www.profoundmedical.com |
Full time employees 142 | Website https://www.profoundmedical.com | ||
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.